<div id="readability-page-1"><div><p>GSK PLC - London-based pharmaceuticals firm - Announces agreement with the US government to lower the cost of prescription medicines for American patients, including GSK's portfolio for respiratory conditions such as asthma and COPD. Says it will lower the price of certain medicines in Medicaid and &#34;launch new products with a more balanced pricing approach&#34;, and will make most of its inhaled respiratory portfolio and other products available to patients on a direct purchasing platform with savings of up to 66%. Furthermore, it intends to further support the US supply chain for critical medicines by securing a reserve of albuterol, the active ingredient used in many inhalers to relieve the symptoms of asthma and COPD, for the US.</p><p>Chief Executive Officer Emma Walmsley says: &#34;Today's announcement builds on GSK's strong track record of increasing access and improving the affordability of its medicines worldwide, including an ongoing commitment to responsible pricing. GSK has been at the forefront of respiratory innovation for decades – helping millions of Americans prevent and treat chronic respiratory diseases such as asthma and COPD. Through this agreement, GSK will ensure patients have access to the current portfolio of respiratory medicines while bringing the next wave of innovation to American patients.&#34;</p><p>Current stock price: 1,822.00 pence, up 0.5% on Friday in London</p><p> 12-month change: up 38%</p><p>By Emma Curzon, Alliance News reporter</p><p>Comments and questions to newsroom@alliancenews.com</p><p>Copyright 2025 Alliance News Ltd. All Rights Reserved.</p></div></div>

葛兰素史克

<p>葛兰素史克（GSK PLC）是一家总部位于伦敦的制药公司，已与美国政府达成协议，以降低美国患者的处方药费用，重点关注哮喘和慢性阻塞性肺病等呼吸系统疾病。该协议包括降低医疗补助计划中的药品价格，并推出具有平衡定价的新产品。GSK 将为其吸入型呼吸药物组合提供高达 66% 的折扣，并为美国确保一批沙丁胺醇。首席执行官艾玛·沃姆斯利（Emma Walmsley）强调了 GSK 对可负担药物获取和呼吸系统创新的承诺</p>

葛兰素史克宣布与美国政府达成药品价格协议